Forum On Fair Drug Pricing Proposes Several Potential Actions For Stakeholders

Intellectual Property Watch: WHO, Stakeholders Take ‘First Step’ On Fair Pricing For Medicines
“The World Health Organization has concluded a major one-day forum on fair pricing of medicines, bringing a wide range of stakeholders together in Amsterdam and coming up with several possible actions for the way ahead. Key points of discussion included a definition of fair pricing, moving away from value-based pricing, delinkage of price from research and development costs, and greater transparency, according to participants…” (Saez/New, 5/12).

Reuters: WHO wants transparency, market revamp for fairer drug pricing
“…Drugmakers are under growing fire as a wave of new treatments for serious conditions like cancer and hepatitis C come to market at sky-high prices, putting them out of reach of many patients and national health services. … WHO Assistant Director-General Marie-Paule Kieny said there was agreement that industry needed reasonable returns on research and development, but governments should play a stronger role in setting prices and directing the drug research agenda…” (Hirschler, 5/11).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.